Lisa Grooms
Family Medicine · New Castle, INNPI 1427587906
Payments from drug & device makers
Across 173 payments — averaging $15.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$654
- Novo Nordisk$263
- Lilly USA, LLC$256
- Astellas Pharma US Inc$234
- Otsuka America Pharmaceutical, Inc.$145
- Pfizer$122
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,728100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 53 | $654 |
| Novo Nordisk | 16 | $263 |
| Lilly USA, LLC | 16 | $256 |
| Astellas Pharma US Inc | 8 | $234 |
| Otsuka America Pharmaceutical, Inc. | 7 | $145 |
| Pfizer | 6 | $122 |
| Novartis | 6 | $101 |
| Boehringer Ingelheim | 6 | $100 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $96 |
| Axsome Therapeutics, Inc. | 6 | $95 |
| Bayer | 6 | $93 |
| Lundbeck LLC | 5 | $78 |
| Corium, LLC | 5 | $65 |
| Alnylam Pharmaceuticals Inc. | 3 | $62 |
| Exact Sciences | 3 | $46 |
| Amarin Pharma, Inc. | 2 | $43 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $37 |
| Abbott | 2 | $36 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Biogen | 1 | $20 |
| Medtronic | 1 | $17 |
| Merck | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| GSK | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 4 | $15 |
| Verona Pharma, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Optinose US, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veozah$125
How this compares
$2,728 in reported general payments places this provider in the 75th percentile of 2,709 family medicine providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 109 | $140,903 |
| MounjaroTirzepatide | 89 | $137,789 |
| JardianceEmpagliflozin | 134 | $131,254 |
| TrulicityDulaglutide | 36 | $75,147 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 89 | $74,730 |
| EliquisApixaban | 56 | $43,107 |
| JanuviaSitagliptin Phosphate | 39 | $32,516 |
| LinzessLinaclotide | 37 | $31,889 |
| RybelsusSemaglutide | 23 | $25,447 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $23,508 |
| FarxigaDapagliflozin Propanediol | 23 | $19,974 |
| Repatha SureclickEvolocumab | 17 | $18,516 |
| TradjentaLinagliptin | 15 | $17,495 |
| Spiriva RespimatTiotropium Bromide | 17 | $17,442 |
| XareltoRivaroxaban | 13 | $16,889 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $256 | $212,936125 claims |
| Novo NordiskOzempic, Rybelsus | $263 | $166,350132 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $100 | $166,192166 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta, Arnuity Ellipta | $16 | $94,017142 claims |
| PfizerEliquis | $122 | $43,10756 claims |
| MerckJanuvia | $17 | $32,51639 claims |
| AbbVieLinzess | $654 | $31,88937 claims |
| AstraZenecaFarxiga | $15 | $19,97423 claims |
| Astellas Pharma US IncMyrbetriq | $234 | $10,42414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in New Castle
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.